A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer

Solid Tumors Clinical Trial

Official title:

An Open-label, Phase I Dose Escalation and Expansion Trial to Investigate Safety and Efficacy of BI 1821736 in Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05839600
• Other study ID #: 1467-0001
• Secondary ID: 2022-502125-17-0
• Status: Recruiting
• Phase: Phase 1
• Start date: May 25, 2023
• Est. completion date: November 22, 2025

Study information

• Verified date: March 2024
• Source: Boehringer Ingelheim
• Contact: Boehringer Ingelheim
• Phone: 1-800-243-0127
• Email: clintriage.rdg[@]boehringer-ingelheim.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is open to adults with advanced solid tumours. People with solid tumours for whom previous treatment was not successful or no treatment exists can take part. The purpose of this study is to find the highest dose of a medicine called BI 1821736 that people with advanced solid tumours can tolerate. BI 1821736 is a type of immunotherapy. It is a special virus that kills cancer cells and helps the immune system fight cancer. In this study, BI 1821736 is given to humans for the first time. Participants receive BI 1821736 as an infusion into a vein about every 3 weeks for up to 3 months. Study doctors regularly check the participants' health and monitor the tumours. The doctors also take note of any unwanted effects that could have been caused by BI 1821736.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 27
• Est. completion date: November 22, 2025
• Est. primary completion date: November 22, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed diagnosis of malignant tumor.
• Advanced, unresectable and/or metastatic or relapsed/refractory solid tumors.
• Has failed conventional treatment or for whom no therapy of proven efficacy exists or who is not eligible for established treatment options. Patient must have exhausted available treatment options known to prolong survival for their disease.
• Has at least one tumoral lesion which is amenable to biopsy.
• Signed and dated, written informed consent form (ICF) in accordance with ICH-GCP and local legislation obtained prior to any trial-specific procedures, sampling, or analyses that are not part of normal standard of practice care.
• Eastern Cooperative Oncology Group score of 0 or 1.
• Adequate organ function or bone marrow reserve defined as demonstrated at screening by

the following laboratory values:

• Absolute neutrophil count (ANC) = 1.5 x 109/L (= 1.5 x 10^3/µL)(= 1500/mm^3); haemoglobin = 90 g/L (= 9.0 g/dL)(= 5.6 mmol/L); platelets = 100 x 10^9/L (= 100 x 10^3/µL)(= 100 x 10^3/mm^3) without the use of haematopoietic growth factors within 4 weeks of start of trial medication.
• Creatinine = 1.5 times the upper limit of normal (ULN).
• Total bilirubin = 1.5 times the ULN, except for patients with Gilbert's syndrome:

total bilirubin = 3 times ULN or direct bilirubin = 1.5 times ULN.

• Aspartate transaminase (AST) and alanine transaminase (ALT) = 3 times ULN if no demonstrable liver metastases, or otherwise = 5 x ULN if transaminase elevation is attributable to liver metastases.
• Partial thromboplastin (PT) / activated partial thromboplastin time (aPTT) <1.5 times ULN unless on a stable dose of an anticoagulant.
• All toxicities related to previous anti-cancer therapies have resolved to = Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 prior to trial treatment administration (except for alopecia and peripheral neuropathy which must be = CTCAE Grade 2 and amenorrhea/menstrual disorders which can be any grade).
• Further inclusion criteria apply

Exclusion Criteria:

• Major surgery (major according to the investigator's assessment) performed within 4 weeks prior to start of study treatment.
• Previous treatment with Vesicular Stomatitis Virus (VSV)-based agents.
• Patients with brain metastases unless they have completed brain radiotherapy and are asymptomatic.
• Radiotherapy within 4 weeks prior to the start of study treatment, except in case of a brief course of palliative radiotherapy (e.g. for analgesic purpose or for lytic lesions at risk of fracture) which can then be completed within two weeks prior to start of study treatment. Note: No radiation must have been given to any lesions planned to be biopsied within 6 months of start of treatment.
• Prior (within 3 weeks of first dose) or concomitant use of systemic corticosteroids (>10 mg daily prednisone or equivalent).
• Prior (within 3 weeks of first dose or less than 5 half-lives) or concomitant use of a medication or a condition considered a high risk for complications from biopsy as per the Investigator's judgement.
• Prior (within 3 weeks of first dose or less than 5 half-lives) or concomitant use of interferon, immunotherapy agents, or tamoxifen.
• Active infection requiring systemic therapy (antibacterial, antiviral, antiparasitic or antifungal therapy) at the start of treatment in the trial.
• Further exclusion criteria apply

Related Conditions & MeSH terms

• Solid Tumors

Intervention

Drug:
• BI 1821736
Solution for infusion

Locations

Country	Name	City	State
Canada	Princess Margaret Cancer Centre	Toronto	Ontario
Spain	Hospital Clínic de Barcelona	Barcelona
Spain	Hospital Quiron. I.C.U.	Barcelona
Spain	Hospital Universitario 12 de Octubre	Madrid
Spain	Instituto Valenciano de Oncología	Valencia
Sweden	Karolinska Universitetssjukhuset Stockholm	Stockholm
United States	Yale Cancer Center	New Haven	Connecticut
United States	NEXT Oncology	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Boehringer Ingelheim

Countries where clinical trial is conducted

United States,  Canada,  Spain,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of Dose Limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) evaluation period		up to 21 days
Secondary	Occurrence of DLTs during the on-treatment period		up to 3 months
Secondary	Occurrence of Adverse Events (AEs) during the on-treatment period		up to 3 months

External Links

•   Related Info